eXoZymes selects Curia to scale up its NCT manufacturing process

eXoZymes ($EXOZ) entered an agreement with contract manufacturer Curia to transfer and scale its NCT production process. Work will take place at Curia facilities in Spain and Italy, covering enzyme production, the cell-free reaction and product purification. The program follows pilot-scale validation and is intended to establish a pathway toward larger-scale manufacturing in 2027.

The partners will also conduct process modeling and engineering analysis to assess the next production scale. Management said the work should support customer qualification and future supply agreements ahead of a planned commercial launch. However, selecting a manufacturing partner is not the same as completing commercialization. The announcement disclosed no contract value, committed customer purchase volumes or revenue forecast, and the larger-scale process still requires transfer, validation and execution.

Sources:

• eXoZymes — Curia manufacturing partnership, Newswire